VE1 AdvisoryEfthymios VogiatzisVE1 Advisory
Let's talk

Efthymios Vogiatzis · Founder, VE1 Advisory · Vienna

A pharmacist's eye on AI, operations and the decisions that depend on them.

I've spent more than ten years taking AI and data products from prototype into production for global life-sciences, biopharmaceutical, insurance and industrial technology companies. Through VE1 Advisory, I help investors, founders and leadership teams check what sits under the model before they commit to it.

Start a conversationRead my writing

Teams and clients across Europe, North America, Asia and South America

Efthymios Vogiatzis in an office setting, looking toward the camera

Impact in numbers

50+

engineers, data scientists and product managers led on a global AI platform

40%

faster delivery after a biopharmaceutical analytics transformation, finished in half the planned time

300,000+

assets risk-assessed worldwide, with organisational risk exposure cut by 40%

€2.5m+

revenue over three years as owner-operator of a healthcare retail business

Results as delivered. Clients and employers anonymised.

Efthymios Vogiatzis in a laboratory

My story

It started with a prescription that looked almost right.

My first job was behind a pharmacy counter, checking doses, interactions and names that read almost like other names. The interesting part was never the obvious one. It was the almost.

Military service as a pharmacist turned that instinct into a discipline: count, sign, reconcile. Then I moved into data, analytics and AI, and found the same habit was worth more in a messy dataset than in a stock room.

You treat the tiny thing as a real problem until it proves harmless.
The full story →

Where I help.

Who I help

Venture capital and private equity investors, pharma corporate venture teams, AI drug discovery founders.

AI drug discovery and technical due diligence

I review the data, validation and claims behind AI drug discovery and life-sciences AI companies, and explain the findings in plain language to the people deciding.

Questions I answer

  • "Does this model learn biology, or errors in the training data?"
  • "Will this data pipeline survive a regulator's data integrity review?"

Built on

Owning a global AI product line in life-sciences instruments, an MPharm (Master of Pharmacy), and seven years as an expert for investors' due diligence projects.

Who I help

Private equity operating partners, leadership teams in life-sciences tools, diagnostics, pharmacy and healthcare.

Operations and data integrity

I reconcile the numbers leadership sees with what's happening on the floor, then make analytics and AI change real decisions.

Questions I answer

  • "Do the key performance indicators (KPIs) in this presentation match the operating data?"
  • "Which AI projects deserve more budget, and which should stop?"

Built on

A biopharmaceutical analytics transformation, a reinsurance data governance framework, running a pharmacy and a diagnostic centre, and an MSc (Master of Science) in Healthcare Operational Management.

Who I help

Scientist-founders, portfolio CEOs and technical leaders who need to be understood by boards and investors.

Scientific and executive communications

I help translate technical risk and scientific milestones into the language of capital, timelines and trade-offs, so good work survives the room it's presented in.

Questions I answer

  • "Why does the board keep misreading our milestones?"
  • "How do I present a pivot or a setback without losing the room?"

Built on

Monthly risk reporting to C-suite executives in industrial technology, decision models for senior biopharmaceutical leadership, and an MBA (Master of Business Administration) in Strategic Management.

Selected work.

Every engagement is anonymised. Clients and employers are described by industry and scope only, never by name or date.

Engagement 01

Life-sciences instruments and software

Taking AI from prototype to production for a global instrument portfolio

5 to 8%

operational efficiency gain, year over year

The mandate
Move a portfolio of AI initiatives across software research and development (R&D), instrument algorithm development and global client services out of the prototype stage and into products customers pay for.
What I did
Owned profit and loss (P&L), product strategy and roadmap for the AI and software-as-a-service (SaaS) product line, and led a global team of 50+ engineers, data scientists and product managers building a commercial data analytics and AI platform.
The result
Predictive analytics, generative AI, computer vision and natural language processing (NLP) shipped into client-facing products serving Standard & Poor's 500 (S&P 500) companies, improving product recommendations, predictive maintenance and automated reporting.
Read the engagement →

Engagement 02

Global biopharmaceuticals

A commercial analytics transformation in half the planned time

60%

fewer customer complaints

The mandate
Rebuild the analytics products used by hospitals, clinics and commercial partners across Europe, Canada, Japan and South America, then running on legacy on-premise systems.
What I did
Led three hybrid teams of 30+ full-time equivalents (FTEs), moved the platform to cloud infrastructure, migrated legacy systems and redesigned data governance.
The result
The transformation finished in half the original timeframe. Delivery speed improved by 40% and customer complaints fell by 60%.
Read the engagement →

Engagement 03

Global industrial technology

Cutting global risk exposure by 40% in a year

40%

lower organisational risk exposure in 12 months

The mandate
Give executives a clear priority order for information security risk across more than 300,000 assets worldwide.
What I did
Ran the risk assessments, built a prioritised remediation roadmap tied to business objectives, and presented monthly risk reports to C-suite executives.
The result
15+ high-risk vulnerabilities identified and mitigated. Related security initiatives consolidated into one product, cutting development costs by 25%.
Read the engagement →

Engagement 04

Healthcare retail (owner-operator)

Running my own healthcare business, with my own money on the line

€2.5m+

revenue over three years

The mandate
Full responsibility for every number in an independent community pharmacy: pricing, purchasing, inventory, cash flow and annual planning.
What I did
Ran the business end to end as owner and managing director, and built commercial campaigns for a base of more than 250 high-value clients a month.
The result
Annual revenue grew by €50,000. The work earned a National Entrepreneurship Award (Top 10 Start-Up Ideas of Greece).
Read the engagement →

The full engagement record →

How I think

Intelligence is the commodity now. The system is the edge.

Every company can rent a frontier model. Few can rent the data discipline and trust around it. These three patterns show up in almost every programme I've worked on.

Illustrative composite, anonymised and normalised to a 0 to 100 index. Not a single client dataset.

Line chart, weeks 1 to 13. Reported index moves between 82 and 86, ending at 85. Actual index falls from 82 to 64. The shaded gap between them widens to 21 points.

The dashboard read 85. The operation was at 64.

Over 13 weeks the gap grew from 0 to 21 points while the reported line barely moved. Most reports don't break. They quietly stop describing reality.

Source: Composite of three anonymised operational reviews in life sciences and industrial technology.

Line chart, weeks 1 to 13. Reported index moves between 82 and 86, ending at 85. Actual index falls from 82 to 64. The shaded gap between them widens to 21 points.

Past V1, you commit. Then you fly.

In aviation, V1 is the speed past which a takeoff can't be stopped. Pilots compute it for this aircraft, this weight, this runway and this wind. That's the arithmetic I bring to a business decision.

  1. 01

    Compute the number

    Data, units and assumptions are reconciled before anyone commits.

  2. 02

    Name the commitment

    What's being decided, by whom, against which trade-offs.

  3. 03

    Fly the aircraft

    I stay through the first quarter, the first board meeting and the first surprise.

Writing.

Efthymios Vogiatzis on a manufacturing floor

16 October 2026 · AI drug discovery · 2 min read

Protein design moved to the atom. The bottleneck moved to the bench.

A new system from the University of Washington designs enzymes atom by atom, which changes the question an investor should ask a drug-discovery founder.

21 October 2026 · Operations · 2 min read

The quiet half of biotech: scaling it next to a sugar mill

A Brevel and Wave Group plant jumps from a 5,000-litre tank to 300,000 litres, on a feedstock sitting next door. Scale-up is the half that decides whether biology reaches a shelf.

September 2026 · Scale · LinkedIn

Trust, speed, and the hard part of scale

Why the organisations that win slow down in the right places.

Field notes by email.

A new essay about once a month on AI, data integrity and the people side of change.

Unsubscribe anytime.

All writing →

On stage and in the room.

October 2026

Invited speaker, 21st Panhellenic Pharmaceutical Congress of the Panhellenic Association of Pharmacists (ΠΕΦ), "Pharma meets AI", Thessaloniki

My talk: "The next drug starts with a different question", on generative AI in drug discovery.

December 2026

Digital World Summit Greece, Athens

Sponsorship coordinator for Greece's national initiative on the governance of new technologies.

digitalworldsummit.gr

2026

Panorama of Entrepreneurship & Career, Athens Concert Hall (Megaron)

Speaker on data and digital strategy.

pan-orama.org

Recognition

National Entrepreneurship Award

Top 10 Start-Up Ideas of Greece.

All speaking →

How a conversation with me usually goes.

  1. 01

    A first conversation

    30 minutes about your situation. You'll know by the end whether I'm the right person.

  2. 02

    A clear diagnosis

    I look at the data, the decision and the people involved, and tell you what I see, plainly.

  3. 03

    Focused work

    We agree the scope together, shaped to the problem: a diligence review, an operational fix, or preparation for a board or investor meeting.

  4. 04

    Through the climb

    I stay involved past the decision, through the first results.

Every conversation is confidential. I'm happy to sign a non-disclosure agreement (NDA) before we start.

If your systems don't quite agree with each other, and everyone has been too polite to say so, let's talk.

Start a conversationConnect on LinkedIn